Praxis Precision Medicines
Yahoo Finance • last month
BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best AI driven biotech stocks to invest in. On June 2, BTIG reduced the price target on Praxis Precision Medicines Inc. (NASDAQ:PRAX) from $843 to $810. The firm maintained a... Full story
- TFC
Mentioned:
Yahoo Finance • last month
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 P... Full story
Yahoo Finance • last month
Stocks Push Higher on US Labor Market Strength and AI Spending
The S&P 500 Index ($SPX) (SPY) today is up +0.24%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.26%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.29%. June E-mini S&P futures (ESM26) are up +0.20%, and June E-mini Nasdaq fut... Full story
Yahoo Finance • last month
Stocks Pressured by Uncertainty of US-Iran Ceasefire Prospects
The S&P 500 Index ($SPX) (SPY) today is down -0.20%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.33%. June E-mini S&P futures (ESM26) are down -0.18%, and June E-mini Na... Full story
Yahoo Finance • last month
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
On May 15, 2026, Exome Asset Management reported selling out of Wave Life Sciences(NASDAQ:WVE), liquidating 421,488 shares in an estimated $5.49 million trade based on quarterly average pricing. What happened According to an SEC filing d... Full story
Yahoo Finance • 2 months ago
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange... Full story
Yahoo Finance • 2 months ago
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, Hi... Full story
Yahoo Finance • 2 months ago
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing da... Full story
Yahoo Finance • 2 months ago
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Se... Full story
Yahoo Finance • 2 months ago
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Key Points Cormorant Asset Management bought 5,800,000 Erasca shares in the first quarter, an estimated $68.55 million trade based on quarterly average pricing. The quarter-end position value rose by $93.84 million, reflecting both share... Full story
Yahoo Finance • 2 months ago
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
What happened According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a new position in Erasca(NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4... Full story
Yahoo Finance • 2 months ago
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encep... Full story
Yahoo Finance • 3 months ago
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best biotech stocks with highest upside potential. As of the close of play on April 24, the broader consensus sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX)... Full story
Yahoo Finance • 3 months ago
Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Praxis Precision Medicines, Inc. (NASDAQ:PRAX) ranks 1st on this list. Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is still pre-revenue but Wal... Full story
- SXTP
Mentioned:
Yahoo Finance • 3 months ago
Praxis Precision Medicines (PRAX): One of the Best Upside Stocks
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 9 Best Upside Stocks to Buy According to Analysts. Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best upside stocks to buy according to analysts. On April 14, Prax... Full story
Yahoo Finance • 3 months ago
Hims & Hers (HIMS) Jumps 48% Ahead of Earnings
Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks With Monster Returns. Hims & Hers saw its share prices jump by 48.3 percent week-on-week as investors positioned portfolios ahead of the results of its earnings performance for t... Full story
Yahoo Finance • 3 months ago
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous sy... Full story
Yahoo Finance • 4 months ago
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price... Full story
Yahoo Finance • 4 months ago
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story
Yahoo Finance • 4 months ago
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside... Full story